Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial
In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with ...
Nov 18, 2026
0
8








